Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TEAD1 | P28347 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 5/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | WRN | Q14191 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31713795 | 0.95 | MAPT (0.37) | MAPTTEAD1POLBTDP1BTK | |
| SCHEMBL31713529 | 0.93 | MAPT (0.36) | MAPTTEAD1POLBTDP1BTK | |
| SCHEMBL31713786 | 0.93 | MAPT (0.36) | MAPTPOLBTDP1BTKRORC | |
| SCHEMBL31713826 | 0.92 | JAK3 (0.38) | MAPTTRPV1BTKTGM2 | |
| SCHEMBL31713763 | 0.92 | EGFR (0.36) | MAPTPOLBTDP1MAPK3BTK | |
| SCHEMBL31713847 | 0.92 | EGFR (0.37) | MAPTPOLBTDP1BTKRORC | |
| SCHEMBL31713931 | 0.86 | MAPT (0.39) | MAPTPOLBTDP1RORCKDM4E | |
| SCHEMBL31713828 | 0.82 | HSD17B10 (0.36) | MAPTPOLBTDP1RORCKDM4E | |
| SCHEMBL31713890 | 0.82 | MAPT (0.39) | MAPTTRPV1KDM4EAKR1B1 | |
| SCHEMBL31664538 | 0.82 | MAPT (0.37) | MAPTTEAD1POLBTDP1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333419-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF WRN | INCYTE CORPORATION (US) | 2025-10-30 | — | — | US | claimed |
| US-20250333419-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF WRN | INCYTE CORPORATION (US) | 2025-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333419-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF WRN | WRN, BLM, RECQL | MAPT 4634/4885TEAD1 1312/4885POLB 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.